The instability of the mitochondrial genome in individuals harboring pathogenic mutations in the catalytic subunit of mitochondrial DNA (mtDNA) polymerase F (POLG) is well recognized, but the underlying molecular mechanisms remain to be elucidated. In 5 pediatric patients with severe myoclonic epilepsy and valproic acidinduced liver failure, we identified 1 novel and 4 previously described pathogenic mutations in the linker region of this enzyme. Although muscle biopsies in these patients showed unremarkable histologic features, postmortem liver tissue available from 1 individual exhibited large cytochrome c oxidase-negative areas. These cytochrome c oxidase-negative areas contained 4-fold less mtDNA than cytochrome c oxidase-positive areas. Decreased copy numbers of mtDNA were observed not only in the liver, skeletal muscle, and brain but also in blood samples from all patients. There were also patient-specific patterns of multiple mtDNA deletions in different tissues, and in 2 patients, there were clonally expanded mtDNA point mutations. The low amount of deleted mtDNA molecules makes it unlikely that the deletions contribute significantly to the general biochemical defect. The clonal expansion of a few individualspecific deletions and point mutations indicates an accelerated segregation of early mtDNA mutations that likely are a consequence of low mtDNA copy numbers. Moreover, these results suggest a potential diagnostic approach for identifying mtDNA depletion in patients.
INTRODUCTION
Mutations in mitochondrial DNA (mtDNA) polymerase F (POLG) have been associated with autosomal dominant progressive external ophthalmoplegia (PEO; MIM 157640) (1, 2) and recessive forms of PEO (2), Alpers-Huttenlocher syndrome (MIM 203700) (3Y6), and an autosomal recessive ataxic syndrome (7) . All affected patients have manifestations of a severe mitochondrial disease with skeletal muscle mainly affected in the various forms of PEO and brain and liver in Alpers-Huttenlocher syndrome. In addition to mutations in POLG, secondary alterations of the mitochondrial genome in these patients have been described. These include i) abundant multiple deletions of mtDNA in skeletal muscle that are a prominent feature of adult patients with PEO (1, 2); ii) certain point mutations, especially in the highly polymorphic noncoding D-loop region, which have also been detected in PEO muscle (8, 9) ; and iii) severe mtDNA depletion described in children with Alpers-Huttenlocher syndrome (3Y6). In cases of mutations in the exonuclease domain of polymerase F, the mtDNA mutations were hypothesized to be consequences of the altered fidelity of the mutated polymerase. Similarly, elevated levels of point mutations in the D-loop region have been detected in skeletal muscle biopsies of adult patients with mutations in the mitochondrial helicase Twinkle (9) , but apparently at different sites. This has raised doubts that the fidelity of the mutated mtDNA polymerase F would be the sole cause of the genetic instability of the mtDNA in these particular patients (9) . In younger patients with severe myoclonic epilepsy of childhood, much less information is available regarding the stability of mtDNA and the particular functional consequences of the mtDNA mutations.
In the present study, we investigated mtDNA depletion and mtDNA mutations and the neuropathologic features of biopsy samples from epilepsy patients harboring POLG mutations. We report clonally expanded mtDNA deletions and point mutations in a broad variety of tissue samples from these patients. The detected mutations that seem to accumulate with the progression of the disease were found to be located at sites that are frequently affected in aging. The observed clonal expansion of aging-associated mutations indicates that the apparent instability of the mitochondrial genome in young patients with POLG mutations may be a consequence of an accelerated segregation of somatic mtDNA mutations due to decreased copy number of the mtDNA.
MATERIALS AND METHODS

Patient Ascertainment
The patients investigated are listed in Table 1 . The control DNA samples for mtDNA copy number assessments were obtained from routine skeletal muscle biopsies from patients without evidence of mitochondrial disease, from surgery samples of patients with temporal lobe epilepsy, from postmortem liver, and from blood samples of patients not suspected of having a mitochondrial disorder. The study was done in accordance with the guidelines of the University Bonn Ethical Commission, and informed consent was obtained from all subjects or from their parents.
Biochemical Investigations
Respiratory chain enzyme activities (rotenone sensitive nicotinamide adenine dinucleotide [reduced form]YCoQ1 oxidoreductase [complex I], cytochrome c oxidase [COX; complex IV]), and citrate synthase in skeletal muscle homogenate were measured spectrophotometrically, as previously described (10) . Results were given in units per gram wet weight and were corrected for potential fiber type variations or adaptational mitochondrial proliferation by normalization of data for the mitochondrial marker enzyme citrate synthase. Histologic and histochemical stainings were performed as previously described (11) .
DNA Mutation Analysis
Whole genomic DNA was extracted from 10-ml aliquots of EDTAYanti-coagulated blood using a salting-out method (12) or from frozen skeletal muscle, liver, brain, buccal swabs, urine sediment, or cultured fibroblasts with the QiaAmp DNA mini kit (Qiagen, Hilden, Germany). The presence of different alleles was determined by restriction fragment length polymorphism analysis of polymerase chain reaction (PCR) fragments. To detect the A467T POLG mutation, primers PG467F and PG467R were used for PCR (all primers used in this study are listed in Table 2 ), and amplification products were digested with restriction endonuclease HaeIII. For the W748S POLG mutation, primers PG748F and PG748R and restriction endonuclease PvuII were used. The E1143G POLG mutation was detected by using primers PG1143F and PG1143R and restriction endonuclease NciI. Amplification conditions for POLG PCR were as follows: 95-C for 3 minutes; 35 cycles of 2 steps at 95-C for 15 seconds and 70-C for 90 seconds; and, finally, 72-C for 7 minutes. Mutation loads of the T72C mtDNA mutation were determined using primers MT72BglF and MT146R and restriction endonuclease BglI. For mtDNA mutation, T152C MT86F and MT152BsrR and restriction endonuclease BsrI were used. Mitochondrial DNA mutation A183G was detected using primers MT183BslF and MT265R and restriction endonuclease BslI. Amplification conditions for mtDNA were as follows: 95-C for 10 minutes; 33 cycles of 95-C for 15 seconds, 55-C for 30 seconds, and 72-C for 1 minute; and, finally, 72-C for 7 minute. Restriction fragments were separated on 10% polyacrylamide gels and visualized by SYBR Green I staining (Sigma-Aldrich, Steinheim, Germany). Proportions of wild-type and mutant mtDNA were estimated from band intensities using the ImageJ analysis software.
Large mtDNA deletions were detected by amplifying overlapping PCR products of 9.5-to 12.7-kb size using JumpStart AccuTaq DNA polymerase (Sigma-Aldrich) and the following primer pairs: MT2623F with MT14695R, MT3922F with MT45R, MT16520F with MT10673R, MT5462F with MT16084R, and MT7027F with MT45R. Amplification conditions were as follows: 95-C for 150 ins53Q/wt; G1791T/wt; T10873C/wt; T11073C/wt; C11741T/wt; ins13710GTAG/wt; A15661G/wt; T15686C/wt; T17241G/wt; G17600A/wt; T17677G/wt seconds; 10 cycles of 92-C for 20 seconds and 68-C for 12 minutes; 20 cycles of 92-C for 25 seconds and 68-C 14 minutes; and 72-C for 11 minutes. Polymerase chain reaction products were separated on 1% agarose gels and visualized with ethidium bromide. If deletions were detected, further primer combinations were used to exclude primer-specific artifacts and to narrow down the location of the individual deletions. To determine deletion breakpoints, deletion-specific DNA fragments were amplified by using a PCR program with shorter extension time. When necessary, multiple bands were separated by excision from agarose gels. Direct sequencing of the purified PCR products was performed on an automatic sequence analyzer by a commercial sequencing service (MWG Biotech, Ebersberg, Germany).
Quantification of Low-Degree Multiple mtDNA Deletions
To quantify multiple mtDNA deletions, we applied a modified version of the single-molecule PCR method (14) . Primers MT3922F and MT45R were used in 42 cycles of the previously described long PCR program to amplify a 12.7-kb-long part of the mitochondrial genome (in the case of Patient p5, additional reactions with primer pair MT2623F and MT14695R were performed). DNA samples were diluted to a degree such that after amplification, in addition to the long wild-type product, only 1 or 2 deletionspecific (i.e. shorter) or no products were detectable in each lane. We assume that under these circumstances, each deletion-specific band is derived from a single deleted mtDNA molecule. Deletion-specific bands were then counted in all lanes, and this number was compared with total mtDNA copy numbers determined in a similar manner but using a higher dilution of the DNA sample (i.e. on average, less than 1 copy of mtDNA per reaction). In the latter reaction, a primer pair (primers MT16520F and MT1144R) was used that spanned the D-loop region and part of the small arc that are very rarely deleted. This gave an amplification product from all types of mtDNA molecules irrespective of whether they were deleted. For example, in the muscle biopsy sample from Patient p1, we found 22 deletion-specific bands in 32 reactions containing altogether 738 pg of total DNA. In the second measurement, we found 24 mtDNAspecific bands in 32 reactions containing 0.738 pg of total DNA. Thus, the ratio between deleted and total mtDNA was (22 / 738 pg) / (24 / 0.738 pg) = 9 Â 10 j4 (0.09%). For each sample, at least 2 experiments were performed using 
independent DNA dilution series. To validate our deletion quantification method, we performed the same previously described procedure on a control DNA mixture created from a DNA sample with a single 3.5-kb mtDNA deletion (previously quantified by Southern blotting and quantitative PCR) and on another sample carrying only nondeleted mtDNA. The calculated amount of the deletion in the control DNA mixture was 0.07%, whereas using our method, it was 0.06%.
mtDNA Copy Number Analysis
We determined mtDNA copy numbers by quantitative PCR using TaqMan probes. Primers MT16520F and MT35R were used together with probe MT16557TM to detect mtDNA. Nuclear DNA content was estimated by amplifying a fragment from the single-copy gene Kir4.1 with primers KIR835F and KIR903R in the presence of probe KIR857TM. The quantitative PCR was performed on the MyiQ real-time PCR system (Bio-Rad, Munich, Germany). Amplification conditions were as follows: 95-C for 3 minutes, and 45 cycles of 95-C for 15 seconds and 60-C for 1 minute. The exact cycle number values were calculated as ln(c) / b, which corresponds to the inflection point of nonlinear fitted regression of the sigmoidal amplification curves applying the following equation:
c ( y 0 , background fluorescence intensity; y, measured fluorescence intensity; x, cycle number; and a, b, and c, curve parameters to be fitted). Calculations were performed using the SigmaPlot 2001 statistical analysis software. For each value, 3 independent experiments were performed with different concentrations of template DNA, each experiment in triplicate, and primer efficiencies were calculated. Serial dilutions from counted fibroblasts or mitochondrial PCR fragments were used to verify absolute copy numbers. 
Statistical Analysis
The mtDNA copy number data were analyzed using the Student t-test. p values of less than 0.05 were considered significant.
RESULTS
Clinical Characteristics and Genotypes of the Patients
The clinical features of the patients studied are summarized in Table 1 . All patients had myoclonic epilepsy and showed certain features of the Alpers-Huttenlocher syndrome (MIM 203700), namely, i) refractory seizures, ii) episodic psychomotor regression, and iii) liver failure in response to valproic acid treatment. Cortical blindness and primary liver disease completing the classic clinical tetrad for classic Alpers-Huttenlocher syndrome (3) were not observed. Sequence analysis of all protein coding exons of the POLG gene revealed that 1 of the patients (p1) was homozygous for a well-known pathogenic POLG mutation, A467T; 3 other patients (p2, p3, and p5) were compound heterozygous, carrying combinations of mutations that had been previously described in association with Alpers-Huttenlocher syndrome. In Patient p4, we identified the known cis mutation pair W748S + E1143G in combination with a novel mutation in exon 13, L752P. Because this latter mutation affects a highly conserved leucine residue in the linker region of the polymerase F, it is very likely that it is relevant for the disease. In addition to the pathogenic mutations, a broad variety of intronic variations and variations in the polyglutamine tract of exon 2 were detected in the POLG gene (Table 1) .
Histologic Evidence of Mitochondrial Impairment
Skeletal muscle biopsies were available for 3 patients (p1, p2, p5; Fig. 1AYD ). The early biopsy from Patient p5 (at the age of 4 years) showed nearly normal histologic features (Fig. 1D) . Biopsies from other patients at later stages of the disease showed several blue-stained COX-negative fibers in the COX/succinate dehydrogenase double-staining preparations (Fig. 1AYC) . Two different skeletal muscle samples were available from Patient p1: 1 biopsy taken at the age of 8 years (Fig. 1A) and a second postmortem sample at the age of 17 years (Fig. 1B) . The greater frequency of COX-negative fibers in the postmortem muscle sample indicates more pronounced mitochondrial impairment with progression of the disease (Fig. 1B) . In agreement with the severe liver manifestations in this patient, COX/succinate dehydrogenase double staining of the postmortem liver sample ( Fig. 2A ; left panel) showed abundant blue COX-negative areas that were not observed in a control postmortem liver specimen ( Fig.  2A ; right panel) from a patient of similar age who died from Lafora disease. Biochemical investigations of the available muscle homogenates showed decreased citrate synthase normalized COX and complex I activities in all patients (Table 3) .
MtDNA Depletion in Various Tissue Samples
To determine the degree of mtDNA depletion, we used a quantitative PCR assay. In this assay, the amount of an mtDNA-specific product was compared with a product specific for a single-copy nuclear reference gene, Kir4.1. All examined tissue samples from patients with pathogenic POLG mutations exhibited lower mtDNA copy numbers compared with corresponding tissues from control individuals (Table 4) ; however, the copy number reduction was not significant in the brain (75% of normal values). Mitochondrial DNA copy numbers in the patients' blood samples were 35% to 55% of the average copy number in controls. All but 1 sample with POLG mutations had lower mtDNA copy numbers in leukocytes than the lowest control values (Fig. 3) . Muscle showed 16% to 55% of normal copy numbers, whereas a very severe depletion was observed in postmortem liver sample from Patient p1 (Fig. 2B) . Only 10% of the mtDNA was preserved in this tissue sample compared with control liver values. The depletion effect was even more dramatic in COX-negative areas of the liver sample in which there were only 5% of normal mtDNA copy numbers left. In COX-positive areas of the same sample, mtDNA depletion was milder as copy numbers were decreased to approximately 23%. There was a progressive decrease in mtDNA copy numbers in the course of the disease in Patient p1. The skeletal muscle biopsy at the age of 8 years showed approximately 50% depletion, whereas in the postmortem skeletal muscle tissue at the age of 17 years, only 16% of mtDNA was left.
Clonally Expanded mtDNA Deletions and Point Mutations
We used long-range PCR to investigate the pattern of deletions in our pediatric patient samples. Different tissues of Patient p5 were compared using 2 different primer pairs for the amplification (Fig. 4A, B) . Similar sets of rearrangements were very prominent in all investigated tissue samples from the same individual. Sequence analysis of both major PCR products confirmed that the same unique rearrangements for this patient were present in all tissues. They consisted of a large deletion between nucleotide positions 2887Y14567 with an inverted insertion 7395Y9299 (Fig. 4A ) and deletion 7391Y15420 (Fig. 4B) . By contrast, in Patient p1, only skeletal muscle contained relatively high amounts of deleted mtDNA molecules (Fig. 4C ). The major bands representing different deleted mtDNA molecules (deletions 5787Y13922 and 6342Y14004, the latter flanked by an 11-nucleotide repeat) were the same in the 2 skeletal muscle samples taken at different ages; only the ratio of the deleted molecules changed with time. The presence of the deletion 6342Y14004 was also confirmed in the brain and liver. To detect individual deletion species in liver, DNA samples were diluted to the extent that only 1 or 2 deletion-specific bands were seen in each lane or there were none at all. Under these circumstances, we assume that deletion-specific bands derive from a single deleted molecule. We found that similar deletions were present in different DNA isolates, and 1 of the deletions was identical to the prominent muscle deletion 6342Y14004 (Fig. 2C) . Two major deletions were detected in skeletal muscle from Patient p2 at positions 5842Y13922 and 6342Y14004 (data not shown).
To compare the amounts of deleted mtDNA molecules in different tissues, we investigated all available samples using a 2-step single-molecule PCR approach (see Materials and Methods section). As shown in Table 5 , the postmortem liver sample of Patient p1 carried 0.02% deleted mtDNA molecules. The minute amount of deleted molecules in comparison with the large COX-negative areas seen in the same sample ( Fig. 2A) makes it improbable that deletions substantially contribute to the biochemical defect in liver. The skeletal muscle sample of the same individual contained 0.08% deletions at the age of 8 years and 0.75% at the age of 17 years. The observed amount of deletions is consistent with the small numbers of COX-negative fibers observed in the patient's muscle, and with the increase in the proportion of COX-negative fibers with age (Fig. 1A, B) , but the reduced activities of respiratory chain enzymes in muscle homogenate cannot be explained by deletions (Table 3) .
It has been reported that individuals with pathogenic POLG mutations often carry mtDNA point mutations especially in the highly polymorphic D-loop region of the mitochondrial genome (8, 9) . We therefore sequenced the Dloop region in all available tissue samples. In 2 of 5 patients (p1 and p2), we found detectable degrees of mtDNA heteroplasmy (i.e. a mixture of wild-type and mutated DNA molecules). One of these individuals (Patient p1) carried mutated alleles at 2 positions: T72C and T152C (Fig. 5A, B) , FIGURE 4 . Clonality of mtDNA deletions in tissue samples from patients harboring pathogenic POLG mutations. Longrange PCR products were separated on an agarose gel. Uppermost bands represent nondeleted mitochondrial genomes (wt); lower bands show the presence of shorter DNA molecules with deletions (del). Region 2623Y14695 (A) and region 7027Y45 (B) of the mitochondrial genome were amplified from Patient p5; region 5462Y16084 was amplified from Patient p1 (C). BL, blood; BR, brain; BS, buccal swab; C, control; FB, fibroblasts; LV, liver; M, molecular weight marker; MB, muscle biopsy; UR, urine. 
Values were determined by a 2-step single-molecule PCR technique as described in Materials and Methods section. Average values from at least 2 independent experiments T SEM are shown. Dashes denote samples that were not available for investigation.
*, For Patient p1, samples taken at the ages of 8 and 17 years were available. mtDNA, mitochondrial DNA; PCR, polymerase chain reaction; SEM, standard error of mean.
whereas Patient p2 harbored A183G (Fig. 5C ). Similar to the deletions, the detected point mutations were specific for the individual, and within the same individual, they were present in all (or at least in more than one) investigated tissues. Comparison of the 2 muscle samples available from Individual p1 demonstrated an increase in mutation loads of both heteroplasmic D-loop mutations over time.
DISCUSSION
In this study, we determined the relationship between quantitative and qualitative defects of mtDNA and the histopathologic findings in a group of young patients who fulfill certain clinical criteria of Alpers-Huttenlocher syndrome, a disease characterized by myoclonic epilepsy and liver failure, the latter frequently observed in response to valproic acid treatment. In each patient, the primary cause of the disease was 2 copies of 5 different pathogenic alleles of the POLG gene, either in homozygous or in compound heterozygous form. The POLG mutations were located in the linker region with the exception of G848S, which maps to the very beginning of the polymerase domain.
We found that all investigated tissues of each patient had lower mtDNA copy numbers than the corresponding tissues from control subjects. The degree of depletion was highly dependent on the tissue type, with the liver being the most severely affected. In the large COX-negative areas of the postmortem liver sample from 1 of the patients, only 5% of normal mtDNA copy numbers were detected. This dramatic depletion is consistent with the patient's hepatic dysfunction and is comparable with previously reported values in similarly affected children (15) . A relatively mild mtDNA copy number decrease was observed in leukocytes in which 35% to 55% of normal values were measured. This effect nevertheless enables a clear distinction between the POLG patient and control groups. Therefore, we suggest that mtDNA copy number measurement in an easily accessible blood sample can provide valuable diagnostic information.
In addition to the depletion of mtDNA, we observed large multiple deletions in postmitotic tissues in all of the patients studied. Multiple mtDNA deletions in postmitotic tissues of adult PEO patients (usually older than 30 years) with pathogenic POLG mutations have been reported in various studies (1, 2, 8, 9, 16, 17) , and the deletions identified in the pediatric patients in the present study were similar to those reported in the adults. Although the specific deletion patterns were different between individual patients, similar patterns were detected in different tissue samples from the same patient. This suggests that the major fraction of the deleted mtDNA molecules originated from a limited number of mutational events during early embryogenesis, that is, before clonal expansion during histogenesis or after birth. Samples from the same individual differed only in the proportions of the same deleted mtDNA molecules, thereby confirming the importance of vegetative segregation and/or relaxed replication in shaping the distribution of deletions within the same individual. If there were extensive ongoing deletion events, a more continuous spectrum of mutations and random differences between tissues samples within the same individual would be expected. The existence of mutational hotspots on the mitochondrial genome could generate a specific pattern of prominent deletions, as suggested for adult PEO patients (1) . This hypothesis would not explain the observation that many prominent deletions were different between different individuals; however, major differences in mtDNA sequence between these individuals and consequent differences in the deletion hotspots would explain our findings. In view of the fact that most (995%) of the mtDNA coding sequence is identical in European subjects, this seems unlikely.
Polymerase F-related multiple deletions have been described in detail in cases of autosomal dominant PEO in which the overall amount of deleted mtDNA molecules can reach up to 60% in skeletal muscle (18) . In these adult autosomal dominant PEO patients, a clustering of deletions near the noncoding D-loop has been observed (16, 17) . In contrast, the deletions found in the pediatric patients investigated in the present study were located far from the D-loop. Importantly, 2 of the deletions reported here have also been found by others to accumulate to high levels in muscle fibers of aged individuals (19) . In contrast to patients with PEO of similar ages (17) , all of our pediatric patients harbored detectable amounts of deletions, but only up to 1% in total. Although it is possible that each deletion contributes to the respiratory chain failure of individual cells resulting in COXnegative, succinate dehydrogenase-positive fibers in the skeletal muscle, the overall levels do not seem to be sufficient to contribute substantially to the general biochemical defect within the tissue as a whole. The biochemical defect observed in the tissue samples in the present study is therefore most likely to be largely, if not completely, due to mtDNA depletion. This is in apparent contradiction to results of a recent study reporting mtDNA depletion in skeletal muscle of only 3 of 7 Alpers-Huttenlocher syndrome patients with POLG mutations (20) . Possible reasons for this difference could include the different combinations of the compound heterozygous mutations and different reference genes in the quantitative copy number assessment (i.e. we used Kir4.1 as established single-copy reference gene).
Point mutations in the noncoding D-loop region of the mitochondrial genome showed a similar tissue distribution to observed mtDNA deletions. We detected substantial degrees of heteroplasmic point mutations in 2 of 5 individuals; 1 of them displayed heteroplasmy at 2 sites. The heteroplasmic mutations were different in the 2 individuals but were detectable in all available tissue samples from the respective patients. Similar to some of the observed deletions, the presence of identical point mutations in different tissues suggests a major role for clonal expansion of mutations created in early development. In line with this concept, an increase in mutation loads of both heteroplasmic point mutations was observed in the course of the disease in Patient p1. Two of the mutated alleles, T72C and T152C, are frequently found in human populations. The third mutation, A183G, has been previously described in PEO patients harboring pathogenic POLG mutations (9) . This mutation is also present, however, in certain human haplogroups (21) . We have also detected heteroplasmy at all 3 previously mentioned D-loop sites in several control individuals older than 40 years (K. G. Hampel, unpublished data); thus, none of these mutations seems to be characteristic for pathogenic POLG mutations. Because deleted mtDNA molecules replicate faster, a small effect of the multiple deletions on the segregation speed of accompanying point mutations, leading to a molecular Bhitch-hiking,[ cannot be excluded.
Secondary changes of the mitochondrial genome described herein and observed by others are not specific features of pathogenic mutations in the POLG gene. Accumulation of both multiple mtDNA deletions and heteroplasmic mtDNA point mutations has been described in the normal aging process (22, 23) . In healthy, aged individuals or in the case of age-dependent neurodegenerative diseases, only very low amounts of deleterious mutations were found in bulk tissues. It has been recently demonstrated, however, that mtDNA mutations can reach functionally relevant degrees in individual cells due to clonal expansion (24, 25) . We found that pediatric patients with POLG mutations exhibit mtDNA damage similar to that observed in normal aging, and that these normally aging-associated changes can be detected during the first 2 decades of life. Because the speed of segregation is higher when the number of segregating units is lower (26, 27) , the observed accelerated accumulation of mutations can be explained by the decreased copy number of mtDNA. Therefore, we suggest that the decreased number of segregating mtDNA molecules has a major influence on the detected pattern of acquired mtDNA mutations, although a possible alteration of the fidelity of POLG cannot be excluded.
In summary, we show that the major effect of the most frequent pathogenic POLG mutations in Alpers-Huttenlocher syndrome is a generalized depletion of mtDNA, which is detectable not only in the liver but also in other tissues, including blood. In addition, our data suggest that the severe mtDNA depletion in this particular disease has a direct effect on the distribution of mtDNA mutations: it leads to an accelerated segregation of specific sets of mutations acquired at a very early stage of life. This process is similar to the clonal expansion of mutated mtDNA observed in adult patients with PEO and during normal aging, but occurs more rapidly.
